As city slicker wrote:

"Prof k Ray last tweet" 

"first proof of concept, huge potential"

along with Bears positive list below:

"In total population, significant elevation in HDL-C, significant lowering of alkaline phosphatase

18% RRR (hazard ratio 0.82) for 3-point MACE in total population (primary endpoint), p=0.11

21% RRR (hazard ratio 0.79) for 3-point MACE in total population (pre-specified sensitivity analysis excluding deaths of undetermined cause), p=0.06.

No appreciable difference for 3-point MACE sub-group analysis between sex, statins or baseline HbA1c above or below the median.

Apabetalone reduced MACE with 40% RRR (hazard ratio 0.6) in those with baseline LDL-C below median, but not in those with baseline LDL-C above median (hazard ratio 1.06). This one is kind of a head scratcher for me right now.....

Apabetalone reduced MACE with 50% RRR (hazard ratio 0.50) in those with baseline eGFR<60, but only by 6% RRR (hazard ratio 0.94) in those with baseline eGFR>60.

Forest plot shows consistent benefit of apabetalone for forest plot of various secondary event endpoints. What stands out is the 41% RRR (hazard ratio 0.59) in total population for first hospitalization for congestive heart failure.

A lot of positives here. 

BDAZ"

Add to this list what you will + anything DM puts out monday morning.More light than darkness IMO.

Big thank you to all the other science minded folks also for stepping up today to help clarify, very much appreciated!!!

glta